Skip to main content
OpenTrials
Completed

NCT Number: NCT04601896

Evaluation of Quality of Life and Its Influencing Factors After VA-ECMO in Refractory Cardiac Arrest Based on SF-36 Score : A Grenoble Cohort Study From 2006 Through 2018

If the ExtraCorporeal Membrane Oxygenation (ECMO) improves survival in the management of refractory cardiac arrest (RCA), this technique is still an invasive technique, not devoid of complications and requiring intensive care that can have serious consequences for patients. If the studies so far show an acceptable quality of life post ECMO in refractory cardiac arrest, the study looks about the quality of life of our patients in Grenoble who survived a refractory cardiac arrest between 2006 and 2018 at the hospital university Grenoble Alps and the factors influencing this quality of life.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Refractory Cardiac Arrest Cardiovascular Diseases Extracorporeal Membrane Oxygenation (ECMO) Heart Arrest Heart Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Chu Grenoble Alpes

Grenoble, 38043, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult >18 years
  • Admission to intensive care unit after a Refractory Cardiac Arrest
  • Hemodynamic instability after resumption of spontaneous cardiac activity.
  • Non-opposition of the patient or his relatives
  • Admission to intensive care unit From 2006 Through 2018

Exclusion criteria

  • ECMO for hypothermia or drug intoxication.
  • Comorbidity contraindicated the ECMO
  • Patients dead before hospital discharge

Treatment and study plan

SF36 questionnaire via telephone interview

Other

SF36 questionnaire via telephone interview

Primary outcomes

  1. Global quality of life score

    Time frame: Through study completion, an average of 3 months

    Items from the SF36 (Short Form 36) survey

Secondary outcomes

  1. Live patients characteristics description

    Time frame: Through study completion, an average of 3 months

    Demographic and clinical retrospective data collection

  2. Vital status

    Time frame: Through study completion, an average of 3 months

    Deed/Lived

  3. Quality of life score related at live patients characteristics description

    Time frame: Through study completion, an average of 3 months

    Items from the SF36 (Short Form 36) survey matched with live patients characteristics description

  4. Quality of life score comparison

    Time frame: Through study completion, an average of 3 months

    Items from the SF36 (Short Form 36) survey compared between the 2 groups ( RCA with /without ECMO) admitted from january 2015 and december 2018

Sponsors and collaborators

Lead sponsor

University Hospital, Grenoble

Other

Registry information

Acronym: AQUA

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Oct 26, 2020
Registry last updated
Apr 30, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.